Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0832

View: 1046 Download: 50 Crossref: 1

Editorial

Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

Clin Mol Hepatol. 2024;30(4):659-662. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0516

View: 1567 Download: 84

Original Article

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 4864 Download: 248 Web of Science: 10 Crossref: 9

Review

Radioembolization for the treatment of hepatocellular carcinoma

Hyo-Cheol Kim

Clin Mol Hepatol. 2017;23(2):109-114. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0004

View: 13745 Download: 377 Web of Science: 51 Crossref: 45

1 |

Viewed By 10931	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7644	MAFLD: How is it different from NAFLD?
Viewed By 5530	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4989	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4895	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 342	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search